Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent
Sometimes stocks making big moves have been hit with an
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.
With that in mind, let's take a closer look at a
is a provider of adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. This stock closed up 4% to 75 cents per share in recent trading.
Thursday's Range: $0.71-$0.77
52-Week Range: $0.30-$0.90
Volume: 3.4 million
Three-Month Average Volume: 1.15 million
From a technical perspective, NBS spiked higher right off its 50-day moving average of 69 cents with monster upside volume. This move also pushed NBS into breakout territory, since the stock flirted with some near-term overhead resistance at 74 cents to 75 cents per share.
Traders should now look for long-biased trades in NBS as long as its trending above its 50-day and then once it sustains a move or close above some more overhead resistance levels at 80 to 85 cents per share with high volume. Look for volume on that move that registers near or above its three-month average action of 1.15 million shares. If that breakout triggers soon, then look for NBS to re-test or possibly take out its next major overhead resistance levels at 90 cents to 96 cents, and possibly even $1 to $1.20.
Due to the large upside volume spike and positive price action on Thursday, this stock will have an increased probability of trading north of $1 if that breakout hits soon.
is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. This stock closed up 12% to $1.28 in recent trading.
Thursday's Range: $1.22-$1.33
52-Week Range: $0.42-$1.96
Volume: 4.5 million
Three-Month Average Volume: 1.2 million
From a technical perspective, CUR is gapped up sharply higher here with above-average volume. This move followed some buying interest the prior day that came in right near its 200-day moving average of 99 cents. Shares of CUR are now pushing within range of triggering a major breakout trade. That trade will hit once CUR manages to clear some near-term overhead resistance levels at $1.38 to $1.55 with high volume.
Traders should now look for long-biased trades in CUR as long as it's trending above some near-term support at $1.20, and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.2 million shares. If that breakout triggers soon, then look for CUR to re-test or possibly take out its next major overhead resistance level at $1.96 to $2.03. Any high-volume move above those levels could send this stock higher towards to $2.70 to $3 in the near future.
is a biotechnology company focused on commercializing its technology, the iBioLaunch platform, for the production of biologics, including vaccines and therapeutic proteins. This stock closed up 5.6% to $1.13 in recent trading.
Thursday's Range: $1.08-$1.14
52-Week Range: $0.65-$2.30
Three-Month Average Volume: 269,706
From a technical perspective, IBIO just bounced hard right off its 200-day moving average of $1.06 with light volume. This move also pushed IBIO right into its 50-day moving average at $1.13.
Traders should now look for long-biased trades in IBIO as long as it's trending above $1.06 to $1.13, and then once it sustains a move or close above some near-term breakout levels at $1.24 to $1.36 with high volume. Look for volume on that move that registers near or above its three-month average action of 269,706 shares. If IBIO clears those levels soon, then this stock will setup to re-test or possibly take out its next major overhead resistance levels at $1.70 to $1.95. Any high-volume move above $1.95 would put $2.30 to $3 into focus for IBIO.
is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. This stock closed up 11.2% to $2.76 in recent trading.
Thursday's Range: $2.53-$2.83
52-Week Range: $0.93-$2.84
Volume: 3.2 million
Three-Month Average Volume: 868,275
Shares of ACAD skyrocketed higher after Roth Capital said a recent article in the journal
could increase use of ACAD's pimavanserin as an off-label schizophrenia treatment. The firm said the changes made to the current study of the drug compared with previous studies should cause it to yield better results.
From a technical perspective, ACAD exploded to the upside right around some near-term support at $2.40 with massive upside volume. This move has now pushed ACAD within range of triggering a major breakout trade. That trade will hit once ACAD manages to clear some near-term overhead resistance at $2.84 with high volume.
Traders should now look for long-biased trades in ACAD as long as it's trending above $2.53, and then once it sustains a move or close above $2.84 with volume that hits near or above 878,275 shares. If that breakout triggers soon, then ACAD will have an excellent chance of re-testing or possibly taking out its next major overhead resistance level at $3.30. If that $3.30 level gets taken out with volume, then this stock could easily spike north of $4 in the near future.
To see more stocks under-$10 that are making notable moves higher today, check out the
portfolio on Stockpickr.
-- Written by Roberto Pedone in Winderemere, Fla.
Follow Stockpickr on
and become a fan on
At the time of publication, author had no positions in stocks mentioned.
Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.